Tandem Diabetes Care Inc (NASDAQ: TNDM) has experienced a decline in its stock price by -0.11 compared to its previous closing price of 18.16. However, the company has seen a fall of -6.93% in its stock price over the last five trading days. zacks.com reported 2025-03-11 that A robust product innovation and several strategic developments raise investors’ optimism for Tandem Diabetes.
Is It Worth Investing in Tandem Diabetes Care Inc (NASDAQ: TNDM) Right Now?
The 36-month beta value for TNDM is at 1.56. Analysts have varying views on the stock, with 10 analysts rating it as a “buy,” 4 rating it as “overweight,” 10 as “hold,” and 0 as “sell.”
The public float for TNDM is 65.93M, and currently, shorts hold a 10.73% of that float. The average trading volume for TNDM on March 11, 2025 was 1.47M shares.
TNDM’s Market Performance
TNDM stock saw a decrease of -6.93% in the past week, with a monthly decline of -49.75% and a quarterly a decrease of -40.07%. The volatility ratio for the week is 5.39%, and the volatility levels for the last 30 days are 6.17% for Tandem Diabetes Care Inc (TNDM). The simple moving average for the past 20 days is -32.29% for TNDM’s stock, with a -52.15% simple moving average for the past 200 days.
Analysts’ Opinion of TNDM
Many brokerage firms have already submitted their reports for TNDM stocks, with Morgan Stanley repeating the rating for TNDM by listing it as a “Equal-Weight.” The predicted price for TNDM in the upcoming period, according to Morgan Stanley is $22 based on the research report published on March 05, 2025 of the current year 2025.
Citigroup, on the other hand, stated in their research note that they expect to see TNDM reach a price target of $24, previously predicting the price at $35. The rating they have provided for TNDM stocks is “Neutral” according to the report published on March 04th, 2025.
Wells Fargo gave a rating of “Equal Weight” to TNDM, setting the target price at $22 in the report published on March 03rd of the current year.
TNDM Trading at -44.25% from the 50-Day Moving Average
After a stumble in the market that brought TNDM to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -66.21% of loss for the given period.
Volatility was left at 6.17%, however, over the last 30 days, the volatility rate increased by 5.39%, as shares sank -48.82% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -51.27% lower at present.
During the last 5 trading sessions, TNDM fell by -7.49%, which changed the moving average for the period of 200-days by -63.44% in comparison to the 20-day moving average, which settled at $26.78. In addition, Tandem Diabetes Care Inc saw -49.64% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at TNDM starting from BLICKENSTAFF KIM D, who sale 30,000 shares at the price of $31.38 back on Nov 21 ’24. After this action, BLICKENSTAFF KIM D now owns 165,190 shares of Tandem Diabetes Care Inc, valued at $941,400 using the latest closing price.
BLICKENSTAFF KIM D, the Director of Tandem Diabetes Care Inc, sale 10,000 shares at $30.00 during a trade that took place back on Nov 20 ’24, which means that BLICKENSTAFF KIM D is holding 195,190 shares at $300,000 based on the most recent closing price.
Stock Fundamentals for TNDM
Current profitability levels for the company are sitting at:
- -0.09 for the present operating margin
- 0.46 for the gross margin
The net margin for Tandem Diabetes Care Inc stands at -0.09. The total capital return value is set at -0.14. Equity return is now at value -33.30, with -10.00 for asset returns.
Based on Tandem Diabetes Care Inc (TNDM), the company’s capital structure generated 0.64 points at debt to capital in total, while cash flow to debt ratio is standing at 0.05. The debt to equity ratio resting at 1.8. The interest coverage ratio of the stock is -14.88.
Currently, EBITDA for the company is -99.13 million with net debt to EBITDA at -5.8. When we switch over and look at the enterprise to sales, we see a ratio of 1.52. The receivables turnover for the company is 9.25for trailing twelve months and the total asset turnover is 1.09. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.93.
Conclusion
In conclusion, Tandem Diabetes Care Inc (TNDM) has had a bad performance lately. Opinion on the stock among analysts is mixed, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
